ReviewFrontiers in immunology2026
The life cycle of tertiary lymphoid structures in pancreatic cancer-a window of opportunity for immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a highly malignant neoplasm with a poor prognosis. The low immunogenicity of the tumor, strong immunosuppression in the tumor microenvironment (TME), and a dense tumor stroma contribute to this outcome. As a result, it is crucial to remodel the pancreatic cancer immune microenvironment to turn "cold" tumors into "hot" ones. The presence of tertiary lymphoid structures (TLS) in the TME is linked to improved prognosis and better patient outcomes. Nevertheless, the complexity of TLS biology presents several critical research gaps. Foremost, among these is the limited mechanistic understanding of how specific components of TLS--such as distinct immune cell subsets, stromal elements and their molecular interactions contribute to either beneficial or adverse clinical outcomes. Furthermore, the temporal dynamics governing TLS induction, maturation, maintenance, and resolution in response to different therapeutic modalities remain poorly elucidated. Another significant area of uncertainty pertains to the precise regulatory pathways that modulate TLS function within the immunosuppressive tumor microenvironment of pancreatic cancer. The classical maturation model of TLS describes a linear development. Based on recent advances in the evolution of TLS, we propose the concept of TLS life cycle in this review which included the tissue-resident memory phase. The mechanisms that direct TLS induction, maturation, maintenance, and resolution after various therapies are then addressed. We also discuss the identification and detection of TLS and elaborate on TLS prognostic value. We synthesize in detail the relationship between TLS and the response to therapy in PDAC. Finally, we present some preclinical evidence favoring the manipulation of TLS function and evolution within the immunosuppressive tumor microenvironment of PDAC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.